Mylan and Biocon submits breast cancer drug application to USFDA

canMylan N.V. and Biocon Ltd. said they submitted Mylan’s biologics license application for a proposed biosimilar Trastuzumab, to the U.S. Food and Drug Administration.

Biosimilar trastuzumab is a proposed biosimilar to branded Trastuzumab, which is indicated to treat certain HER2-positive breast and gastric cancers.

HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells.

Mylan and Biocon said that this has the potential to be the first submission of a proposed biosimilar trastuzumab in the U.S.

Mylan President Rajiv Malik said, “The FDA submission for biosimilar trastuzumab marks Mylan’s first FDA biosimilar submission from our broad portfolio of biosimilar products in development and our product has the opportunity to be the first biosimilar trastuzumab approved in the U.S.”

“Our trastuzumab biosimilar is already being sold in 11 developing markets, including India, and we look forward to bringing the product to market in the U.S. and Europe upon approval.”

The submitted license application includes a package of analytical similarity, nonclinical and clinical data. The clinical data consists of two pharmacokinetic studies and the heritage confirmatory efficacy and safety trial.

The results of the heritage trial were presented at this year’s American Society of Clinical Oncology (ASCO) annual Meeting and the European Society for Medical Oncology (ESMO) Congress.

Dr Arun Chandavarkar, CEO & Joint MD, Biocon, said, “Cancer patients in India and emerging markets have benefited with our trastuzumab and this advancement in the U.S. will enable us to enhance access to this affordable therapy to larger patient pools.”

Mylan and Biocon are partners on a portfolio of biosimilar and insulin products. The proposed biosimilar trastuzumab is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace.

Mylan has commercialization rights for the proposed biosimilar trastuzumab in the U.S., Canada, Japan, Australia, New Zealand and in the European Union and European Free Trade Association countries.

Biocon has co-commercialization rights with Mylan for the product in the rest of the world.

Mylan is a global pharmaceutical company which offers a more than 2,700 generic and branded pharmaceuticals, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS worldwide depend.

It has markets in more than 165 countries and territories with 40,000 employees.

Biocon Limited is India’s largest and fully-integrated biopharmaceutical company.

Some of its key brands are INSUGEN (rh-insulin), BASALOG (Glargine), CANMAbTM (Trastuzumab), BIOMAb-EGFRTM (Nimotuzumab) and ALZUMAbTM (Itolizumab), an anti-CD6 monoclonal antibody.



Alembic Pharmaceuticals receives FDA approval for hypertension tablets Alembic Pharmaceuticals Ltd said it received approval from the United States Food & Drug Administration for its abbreviated new drug application for Telmisartan and Amlodipine tablets for hypertension.The Telmisartan and Amlodipine Tablets are equivalent to the Twynsta tablets of Boehringer Ingelheim Pharmaceuticals, Inc.An Abbreviated New Drug ...
Dr Reddy’s Labs launches osteoporosis drug in the US Dr Reddy's Laboratories Ltd said it launched raloxifene hydrochloride tablets --used to treat osteoporosis -- in the US market.Raloxifene hydrochloride tablets are a therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets. A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, r...
Marksans Pharma gets USFDA approval for synthetic Vitamin D tablets Marksans Pharma Ltd said the United States Food & Drug Administration has given its approval for its paricalcitol capsules -- a synthetic equivalent of Vitamin D.Vitamin D is important for the absorption of Calcium from the stomach and for the functioning of Calcium in the body. Paricalcitol Capsules are therapeutically equivalent to the reference l...
Almebic Pharmaceuticals receives inspection report from USFDA Alembic Pharmaceuticals Ltd., said it received an Establishment Inspection Report from the United States Food and Drug Administration for the inspection carried out at their formulation facility at Panelav, Gujarat.The FDA has the authority to inspect any establishment in which food is manufactured, processed, packed, or held, in search of contamination....
Shilpa Medicare receives USFDA approval for generic bone marrow drug Shilpa Medicare Ltd said it received an approval from the United states Food & Drug Administration for Azacitidine injection.Azacitidine is used to treat myelodysplastic syndrome - a group of conditions in which the bone marrow produces blood cells that are misshapen and does not produce enough healthy blood cells.The approval was received under ...
Lupin receives FDA approval for generic Namenda XR dementia capsules Pharma Major Lupin Ltd said it received final approval from United States Food and Drug Administration for selling Memantine Hydrochloride extended-release capsules, a generic version of Allergan’s Namenda XR capsules.Namenda XR extended-release capsules are approved by the USFDA for the treatment of moderate to severe dementia of the Alzheimer's disea...
Aurobindo Pharma to launch HIV drug in Africa this year, gets tentative FDA nod Aurobindo Pharma Limited, a pharmaceutical manufacturing company based in Hyderabad, said it received a tentative approval for HIV drug Dolutegravir from US Food & Drug Administration.It is the first FDA approval of a generic version of Dolutegravir. Through a tie up with ViiV and the Clinton Health Access Initiative, Inc., the product is expected...
Sharon Bio Medicines receives FDA approval for Tajola API plant Indian Pharmaceutical company Sharon bio medicine Ltd said it received the Establishment Inspection Report (EIR) from United States Food and Drug Amnistration for its manufacturing plant located at Tajola in Raigad Dist., Maharashtra.The plant, which will make Active Pharmaceutical Ingredients is now approved by the USFDA and the generic drug user fee is...
Dr Reddy’s Laboratories launches Paricalcitol injection in the US Market Dr. Reddy's Laboratories Ltd said it launched Paricalcitol Injection, a therapeutic equivalent generic version of Zemplar injection in the United States market approved by the US Food & Drug Administration (USFDA).The Zemplar brand and generic had US sales of approximately $22.5 million for the most recent twelve months ending in July 2016 according ...
Lupin receives tentative approval for generic Avelox tablets Pharma Major Lupin Limited announced that its US subsidiary, Gavis Pharmaceuticals received a tentative approval from the US FDA for selling Moxifloxacin hydrochloride tablets, a generic version of Bayer Healthcare Pharmaceuticals' Avelox tablets.Lupin’s Moxifloxacin hydrochloride tablets are the AB rated generic equivalent of Bayer Healthcare Pharma...
Dr. Reddy’s Laboratories launches heart drug in the US Pharma company Dr. Reddy's Laboratories Ltd said it launched Nitroglycerin sublingual tablets -- a therapeutic equivalent generic version of Nitrostat sublingual tablets -- in the US market.The medication is used before physical activities (such as exercise, sexual activity) to prevent chest pain (angina) in people with a certain heart condition (coronar...
US FDA updates warning against widespread use of fluoroquinolones The US Food & Drug Administration issued a warning against casual usage of fluoroquinolone antibiotics, arguably the most widely used broad-spectrum antibiotic in India.USFDA advised that the side effects caused by the use of fluoroquinolone antibacterial drugs would outweigh the benefits for patients who have alternative treatment options.Patien...
Lupin receives tentative US FDA approval for generic version of Paxil Indian pharma major Lupin Ltd announced today that it received tentative approval from the United States Food & Drug Administration to market a generic version of Apotex Technology's 'Paxil' Paroxetine tablets.The medicine is indicated for the treatment of major depressive disorder, panic disorder, social anxiety disorder and premenstrual dysphoric d...
EMA accepts review for Mylan and biocon’s trastuzumab biosimilar Mylan N.V. and Biocon Ltd. said the European Medicines Agency accepted for review Mylan’s Marketing Authorization Application for a proposed biosimilar version of biosimilar Trastuzumab, a medicine used to treat breast and gastric cancers.This is the second biosimilar submission developed by the partnership that has been accepted for review in Europe. M...
Stride Shasun receives USFDA approval for constipation treatment Pharma company Strides Shasun announced that it received the United States Food & Drug Administration (USFDA) approval for Polyethylene Glycol powder to treat occasional constipation.The powder when consumed as a solution works by softening the stool and increasing the frequency of bowel movement by retaining water in the stool, added the company. ...